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Epidermolysis bullosa with muscular dystrophy
(EB-MD) is a distinct variant of EB caused by
mutations in the plectin gene (PLEC1). In this study,
we have examined two Japanese patients with EB-MD
using heteroduplex scanning or a protein truncation
test for mutation detection analysis. The results
revealed that both patients were compound heterozy-
gotes for novel PLEC1 mutations (Q1936X/Q1053X
Epidermolysis bullosa with muscular dystrophy(EB-MD) is a distinct variant of EB, inherited in anautosomal recessive pattern (for a recent review, seeUitto et al, 1996). Clinically, the affected individualsdemonstrate blistering of the skin and mucous
membranes, usually noted at birth or shortly thereafter. These
cutaneous changes are associated with nail dystrophy and enamel
hypoplasia. Characteristically, later in life a progressive muscle
weakness ensues, but the time of onset of the muscle involvement
is highly variable. In some cases, the muscle weakness has been
noted during the early infancy, whereas in others it is not
recognized until the second or third decade of life. The reasons
for the variability of onset of muscular dystrophy are unclear,
but in most cases the muscle involvement results in profound
weakness, and the patients ultimately become wheelchair bound.
Electron microscopy of the skin in patients with EB-MD has
demonstrated tissue separation in the lower portion of the
basal keratinocytes, just above the attachment plaques of the
hemidesmosomes (McLean et al, 1996; Pulkkinen et al, 1996;
Smith et al, 1996). Consequently, EB-MD was initially classified
as a simplex variant of EB, but more recent molecularly based
classification has designated it as a hemidesmosomal variant
(Pulkkinen and Uitto, 1998). Initial immunofluorescence revealed
absent or moderately attenuated staining with antibodies recogniz-
ing plectin or its variant HD1, a multifunctional attachment
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and R2421X/12633ins4), which all caused premature
termination of translation of the corresponding poly-
peptides. These cases, which demonstrate the utility
of two complementary mutation detection strategies,
add to the repertoire of plectin mutations in EB-MD.
Key words: blistering skin diseases/mutation detection strat-
egies/plectin mutations. J Invest Dermatol 112:109–112, 1999
protein present in the dermal–epidermal junction (Gache et al,
1996). This protein is also expressed in the sarcolemma and the
Z-lines of the muscle, and the expression in patients with
EB-MD in the muscle was also shown to be negative (Chavanas
et al, 1996; Smith et al, 1996). These observations suggested
that plectin is a potential candidate gene/protein system at fault
in EB-MD. Subsequent cloning of the human plectin gene
(PLEC1) allowed development of mutation detection strategies
that were applied to EB-MD (Liu et al, 1996; McLean et al,
1996). These initial strategies consisted of polymerase chain
reaction (PCR) amplification of genomic sequences, followed
by heteroduplex scanning and direct automated nucleotide
sequencing (McLean et al, 1996; Pulkkinen et al, 1996; Smith
et al, 1996). Subsequently, a protein truncation test (PTT) for
the two large 39 exons (32 and 33) of the plectin gene was
developed (Dang et al, 1998). Utilization of these strategies
enabled specific mutations in the plectin gene to be disclosed,
and the majority of the mutations were stop codon or premature
termination codon-causing mutations within exon 32 (for a
summary, see Pulkkinen and Uitto, 1998).
In this study, we have examined two Japanese patients with
EB-MD, and we were able to identify novel plectin mutations
in each of the four alleles.
MATERIALS AND METHODS
Clinical features
Patient 1 The proband is a 9 y old Japanese male, the third child of
clinically normal parents, with two older brothers who were clinically
normal. The proband’s father and the maternal grandfather were first
cousins (Fig 1A). Blistering and erosions of the skin were noted at birth,
together with nail dystrophy. General muscle weakness was noted during
infancy, and the muscle weakness progressed so that at 9 y of age he had
major difficulties in walking. He also has tooth decay and nail dystrophy,
as well as urethral strictures that require frequent hospitalizations.
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Figure 1. Mutation detection in family
1 by heteroduplex scanning. (A)
Pedigree of the family with the proband
(arrow) with epidermolysis bullosa with
muscular dystrophy. (B) Heteroduplex
analysis by CSGE of PCR products
corresponding to exon32of theplectin gene
(upper panel) revealed heteroduplex bands
in the case of the proband (III-3), his father
(II-1), and an older brother (III-1), whereas
other family members tested showed
homoduplex band only, similar to that in
an unrelated healthy control (C). CSGE of
PCR products corresponding to exon 25
(lower panel) revealed heteroduplex bands
in addition to the proband (III-3), in the
mother (II-2) andanotherolderbrother (III-
2). (C, D) Direct nucleotide sequencing of
the PCR products depicting heteroduplexes
indicated that the paternal mutation was a
heterozygous C-to-T transition at
nucleotide position 5806, a mutation
designated Q1936X. The maternal
mutation was a C-to-T substitution at
nucleotide position 3157, a mutation
designated Q1053X. Thus, the proband in
family 1 was a compound heterozygote
Q1936X/Q1053X.
Diagnostic transmission electron microscopy of the patient’s skin
revealed blistering at the level of the lower portion of the basal
keratinocytes. Immunofluorescence staining of the skin with antibodies
for plectin (5B3 and 10F6; kindly provided by Dr. Gerhard Wiche,
University of Vienna, BioCenter, Vienna) or HD1 (121, E2, K15, and
156; kindly provided by Dr. Katsushi Owaribe, Nagoya University,
Nagoya, Japan) was entirely negative. Staining of the proband’s skin
with a battery of other antibodies, including those recognizing laminin
5, type VII collagen, α6β4 integrin, BPAG1, BPAG2, and uncein
epitopes, were positive (data not shown).
Patient 2 The proband is a 33 y old Japanese male, the second child of
unrelated, clinically normal, parents. The older brother was also clinically
unaffected. Blistering of the skin was first noted within a few days of birth,
and the patient also exhibited nail dystrophy and partial scarring alopecia.
First signs of muscle weakness in the proximal extremities were noted at
the age of 5 y. The muscle weakness became pronounced at the age of
17, and the patient was unable to walk at the age of 22. Immunofluoresence
staining of the proband’s skin with the same antibodies for plectin and
HD1, as were used in case 1, was completely negative, whereas a variety
of other basement membrane zone antibodies resulted in positive staining
(data not shown).
Mutation detection strategies DNA was isolated from peripheral blood
from the two probands and their immediate family members. DNA from
unrelated healthy individuals served as control. In case 1, the mutation
detection strategy consisted of PCR amplification of exonic sequences,
and the PCR products were subjected to heteroduplex analysis by con-
formation-sensitive gel electrophoresis (Ganguly et al, 1993). PCR ampli-
fication of exons 25 and 32, which were shown to contain the mutations
in this case (see Results), was performed with the following primer pairs.
Exon 25: sense, 59-AGGACCGGCTGATGGCTGAG-39; anti-sense, 59-
AAGACAGGGAGTGGGAAGC-39. Exon 32 (nucleotides 5786–6191):
sense, 59-CGCAACACAAGGCTGACATC-39; anti-sense, 59-TCCTCC-
ACGTTGGCTTTCAG-39. The PCR products were subjected to direct
automated nucleotide sequencing (PE Applied Biosystems, Foster City, CA).
In case 2, PTT was applied to cover two large 39 exons, numbers 32
and 33, by PCR amplification in two or three overlapping fragments,
respectively. The forward primers (see below) were created to include the
59 sequence of the corresponding fragment preceded by a T7 promoter
sequence (underlined) and a eukaryotic translation initiation codon (bolded)
(Hogervorst et al, 1995; Dang et al, 1998). The reverse primers 32 were
created to correspond to the 39 intronic sequences with the addition of a
downstream stop codon or they contained the natural stop codon (double
underlined). The reverse primer for exon 33 was designed to correspond
to the intronic sequences 39 and to include a naturally occuring stop codon
at the end of exon 33. Specifically, the primers were: (L; exon 32)
59-GCTAATACGACTCACTATAGGAACAGACCACCATGTTCCG-
CGAGCTGGCCGAGG-39; (R; exon 32) 59-TCAACCCACCAAAG-
CAGATCC-39; (L; exon 33) 59-GCTAATACGACTCACTATAGG-
AACAGACCACCATGCTGGGCTTCCACCTTCCC-39; (R; exon 33)
59-GTGTGAGTGGCAGGTAGAAGG-39.
The PCR conditions were: 94°C, 5 min; followed by 94°C, 45 s; 60°C,
30 s; 68°C, 2.5 min (38 cycles). Four hundred nanograms of genomic
DNA and 20 pmol of each primer were used in a 50 µl PCR reaction
mixture containing 10 mM dNTP, 1.75 mM MgCl2, and 3.5 U of Expand
Long Template PCR System polymerase enzyme (Boehringer, Indianapolis,
IN). Genomic segments corresponding to these exons were PCR amplified,
and the PCR products were used directly as templates in a coupled
transcription/translation reticulocyte lysate system reaction with S35-labeled
methionine, according to the supplier’s protocol (TnT/T7; Promega,
Madison, WI). The radiolabeled translation products were examined on
10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The gels
were fixed with 40% methanol/10% acetic acid, dried under vacuum, and
exposed on X-OMAT AR film (Eastman-Kodak, Rochester, NY) for 14–
16 h at room temperature. When evidence for a truncated polypeptide
was observed, the corresponding PCR products were subjected to direct
nucleotide sequencing.
RESULTS AND DISCUSSION
Two Japanese patients with EB-MD were subjected to mutation
detection analysis using strategies described in Materials and
Methods. In case 1, scanning of plectin genomic sequences
by conformation-sensitive gel electrophoresis (CSGE) revealed
heteroduplex bands in the case of exons 25 and 32 (Fig 1B).
Specifically, CSGE of exon 32 revealed heteroduplex bands in
the case of the proband (III-3), his oldest brother (III-1), and
the father (II-1), whereas the mother (II-2) and the middle
brother (III-2) showed homoduplex band only, similar to that
noted in an unrelated healthy control (C). Direct nucleotide
sequencing of the PCR products indicated that the individuals
demonstrating the heteroduplex band were heterozygous for a
C-to-T transition in nucleotide position 5806 (Fig 1C). This
nucleotide substitution results in change of a codon for glutamine
(CAG) to a stop codon (TAG), and this mutation was designated
as Q1936X. This mutation was predicted to truncate the protein
polypeptides so that the molecule lacks the carboxy-terminal
end of the rod domain and the entire carboxy-terminal
intermediate filament-binding domain. The rod domain of plectin
may be important in plectin dimerization, as antibodies directed
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Figure 2. Mutation detection in family
2 by protein truncation test. (A) The
nuclear family consisted of the proband
(arrow), an older brother (II-1), and clinically
unaffected parents (I-1 and I-2) who were
not related. (B) Protein truncation test
corresponding to exon 32 sequences
revealed a truncated polypeptide of 66 kDa
in case of the proband (lane 2), as compared
with a 78 kDa band in a normal control (lane
1). Test of exon 33 sequences revealed a
shortened polypeptide of 44 kDa in the case
of the proband (lane 4), as compared with a
control (lane 3) that showed the expected
size band of 81 kDa and a slightly faster
migrating band. (C) Sequencing of the
regions of the gene predicted to contain stop
codon mutations on the basis of the size of
the shortened polypeptides revealed a
paternal C-to-T transition resulting in
substitution of a codon for arginine by a stop
codon, amutation designatedR2421X.The
maternal mutation was shown to be a 4 bp
insertion at nucleotide position 12633,
resulting in a premature stop codon 120
nucleotides downstream from the insertion.
Thus, the proband in family 2 was a
compound heterozygote R2421X/
12633ins4.
against epitopes within this domain have been found to disrupt
self-association of plectin (Foisner et al, 1991).
Scanning of exon 25 by CSGE revealed heteroduplex bands
in the case of the proband (III-3), as well as the middle brother
(III-2) and the proband’s mother (II-2) (Fig 1B). Sequencing
of the corresponding PCR products revealed a C-to-T transition
at position 3157 (Fig 1D). This nucleotide substitution also
results in a change of a codon for glutamine (CAG) to a stop
codon (TAG), and this mutation was designated as Q1053X.
This mutation eliminates most of the functional domains of the
plectin polypeptide, including coiled-coil rod domain and
carboxy-terminal intermediate filament-binding domain. Thus,
the Proband 1 is a compound heterozygote for two stop codon
mutations, Q1936X/Q1053X.
In case 2, an initial search for mutations by CSGE was
unyielding, and subsequently, PTT was used as an alternate
strategy to examine exons 32 and 33. Protein products obtained
from coupled transcription/translation of PCR fragment spanning
the 39 side of exon 32 revealed evidence for synthesis of a
shortened polypeptide. Specifically, the full-length protein product
was expected to be µ78 kDa, whereas in the case of the
proband, a shortened polypeptide of µ66 kDa was noted
(Fig 2B, lanes 1 and 2, respectively). Sequencing of the mutated
region of the PCR product corresponding to the truncated
polypeptide revealed a C-to-T transition at nucleotide position
7261, which resulted in substitution of a codon for arginine
(CGA) by a stop codon (TGA) (Fig 1C) within the carboxy-
terminal end of the rod domain. Direct sequencing of the
corresponding segment in other family members revealed that
the father (I-1) and the older brother (II-1) were heterozygous
carriers of this mutation.
Examination of exon 33 sequences by PTT revealed evidence
for a shortened polypeptide. PCR amplification spanning the 39
side of exon 33 showed single bands of 2457 bp for the proband
and the control on a 0.8% agarose gel (data not shown). Protein
products of the proband’s DNA revealed a shortened polypeptide
of µ44 kDa, the full-length protein product being estimated to
be µ81 kDa (Fig 2B, lanes 3 and 4). Direct nucleotide
sequencing of the corresponding PCR product revealed a 4 bp
insertion (AGAC) at nucleotide position 12633 (Fig 2C). This
insertion resulted in a frameshift that caused a 39-amino acid
missense sequence, followed by a premature termination codon
(TGA). Direct nucleotide sequencing of the corresponding
segment in members of the nuclear family revealed that the
mother was a heterozygous carrier of this mutation 12633ins4,
whereas the father and the older brother had corresponding
wild-type allele only. The 12633ins4 is the first mutation found
in exon 33 of the plectin gene. This mutation results in
truncation of the end of the carboxy-terminal globular domain,
which plays an important role in association with intermediate
filaments (Wiche et al, 1993). Thus, the proband in family 2
was a compound heterozygote for nonsense and premature
termination codon-causing mutations, R2421X/12633ins4, in
the plectin gene.
Previously nine distinct mutations have been disclosed in the
plectin gene in patients with EB-MD (Pulkkinen and Uitto,
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1998). The addition of the four novel PLEC1 mutations detected
in this study significantly contributes to the repertoire of the
EB-MD database. Among the eight previous cases, only one,
reported by Dang et al (1998), was a compound heterozygote,
whereas the remaining cases were homozygous for the mutations.
Interestingly, in case 1 of our study, the father and the maternal
grandfather were first cousins, yet the maternal and paternal
mutations of the proband were different.
Two independent, complementary mutation detection strategies
were employed in this study. In the first case, a strategy based
on PCR amplification of PLEC1 genomic sequences, followed
by heteroduplex scanning and automated nucleotide sequencing,
was utilized. This strategy allows expedient scanning of exonic
sequences for heterozygous sequence variants (Ganguly et al,
1993), but PCR amplification of segments of large exons, such
as exons 32 and 33 in PLEC1, is difficult due to the highly
repetitive nature of the plectin gene that is particularly GC rich
(McLean et al, 1996). Furthermore, all sequence variants do not
result in the formation of detectable heteroduplexes under the
CSGE conditions utilized, as illustrated by case 2 in this study.
Secondly, PTT was applied to examine exons 32 and 33 for
premature termination codon-causing mutations in case 2. This
technique utilized PCR fragments of up to 1.5 kb, thus requiring
fewer PCR reactions. A general weakness of PTT is that it will
not detect missense mutations or common polymorphisms, and
it may not detect small in-frame insertions or deletions, such as
a previously described homozygous 9 bp deletion in a Japanese
patient with EB-MD (Pulkkinen et al, 1996). In such cases,
heteroduplex scanning is more likely to find the mutations.
Nevertheless, use of these complementary technologies was
clearly successful in disclosing mutations in the plectin gene and
can be applied to further cases. Identification of additional
mutations in PLEC1 in patients with EB-MD will be helpful
in further delineation of genotype/phenotype correlations. This
aspect is particularly important in view of the fact that all
EB-MD patients evaluated thus far have cutaneous blistering
noted at birth or shortly thereafter, whereas the onset of muscle
involvement is highly variable, ranging from early infancy to
the third decade of life (Uitto et al, 1996). Thus expansion of
the mutation database is critical for prognostication of the
phenotypic progression of this devastating genetic disease involving
the skin and the muscle.
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